Table 3 Summary of adverse events (treated set)
|  | Linagliptin 5 mg | Glimepiride 1–4 mg | Placebo |
|---|---|---|---|
Patients (n) | 40 | 41 | 40 |
Any adverse events (%) | 27.5 | 61.0 | 35.0 |
Severe adverse events (%) | 0.0 | 0.0 | 0.0 |
Drug-related adverse events (%) | 17.5 | 43.9 | 10.0 |
Other significant adverse events (according to ICH E3) (%) | 0.0 | 2.4 | 2.5 |
Adverse events leading to discontinuation of trial medication (%) | 0.0 | 0.0 | 2.5 |
Adverse events of special interest* (%) | 0.0 | 4.9 | 10.0 |
Serious adverse events (%) | 0.0 | 0.0 | 0.0 |